Verified factor-similar pair

VBK vs VXF

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
85
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • VXF has the higher backtested relative Sharpe (0.938 vs 0.748).
  • VXF is cheaper on dividend valuation (126 vs 131, where 100 is each fund's historical median).
  • VXF has the stronger regression fit (adjusted R-squared 0.972 vs 0.965).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

VBK

Vanguard Small-Cap Growth ETF
SMB
Adj. R2
0.965
Rel. Sharpe
0.748
Mkt beta
1.06
AUM
US$21.1B
MER
0.05%
Valuation
131

VXF

Vanguard Extended Market ETF
SMB
Adj. R2
0.972
Rel. Sharpe
0.938
Mkt beta
1.03
AUM
US$26.8B
MER
0.05%
Valuation
126

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
VBK
+0.69
|t|
+23.7
VXF
+0.60
|t|
+26.3
diff +0.09
HML
VBK
-0.19
|t|
-6.8
VXF
+0.02
|t|
+0.8
diff -0.21
RMW
VBK
-0.18
|t|
-5.2
VXF
-0.05
|t|
-1.9
diff -0.13
CMA
VBK
-0.07
|t|
-1.6
VXF
-0.13
|t|
-3.9
diff +0.06
UMD
VBK
+0.04
|t|
+2.3
VXF
+0.02
|t|
+1.5
diff +0.02

Why This Pair Matches

Exposure level
82
Exposure shape
97
Mkt beta diff
0.03
Rel. Sharpe diff
0.190

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

VBK fund page VXF fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.